news
A2aAR protein holds clues for better drug design
Scientists have investigated a key protein used in drug design and discovered dynamic structural features that may lead to new ways to target diseases...
List view / Grid view
Drug Discovery
In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which new candidate medications are discovered.
news
MG1 virus destroys HIV-infected cells that standard therapies can’t reach
Researchers from Canada try a new approach to eliminate dormant HIV-infected cells from the body using the MG1 virus.
article
Expert view: Conquering late stage failures with advanced hit-to-lead techniques
Failing early in drug discovery is the primary driving force for new techniques in the hit-to-lead phase.
article
Patient-derived neural progenitor cells as a drug discovery model for mitochondrial diseases
Mitochondrial DNA (mtDNA) mutations cause severe disorders that are untreatable and mostly affect the nervous system. The difficulty in funding therapies may also be explained by the lack of viable modelling systems...
article
Expert view: Optimising the hit-to-lead workflow
Hits identified in high-throughput screens are evaluated within the hit-to-lead phase of drug discovery, where they undergo an iterative optimisation process employing a variety of techniques to identify promising lead compounds to move forward to the lead optimisation phase.
article
Using bioinformatics sequence similarities to optimise repurposing activities
A significant amount of selectivity and potency data originating from screening of drug targets is generated each year and deposited in public databases. This can be exploited to accelerate drug discovery, in particular, for a variety of repurposing activities...
article
Expert view: Addressing the big challenges in drug screening
One of the biggest challenges facing drug discovery across all therapeutic modalities (small molecule, biologics, and cellular) remains the balance between physiological relevance and throughput.
article
Q&A: Integrated drug discovery panel – your questions answered
Drug discovery from concept to drug candidate has become a collective effort where multi-disciplinary project teams from CROs work with drug companies and academia to deliver clinical candidates, overcoming multi-factorial research obstacles along the way.
article
Expert view: Improving hit-to-lead results
Declining R&D productivity is a key challenge in the pharmaceutical industry today.
article
Informatics In-Depth Focus 2017
In this In-Depth Focus we look at using bioinformatics sequence similarities to optimise repurposing activities; informatics infrastructure in neglected disease research, and machine learning for accelerating drug discovery.
article
Drug Target Review – Issue #4 2017
Issue 4 of Drug Target Review looks at artificial intelligence in drug discovery and features In-Depth Focuses on Screening, Hit to Lead and Informatics.
whitepaper
Whitepaper: In search of a disease-modifying agent for Parkinson’s disease: a discovery story
Are selective, brain-penetrant inhibitors of LRRK2 an answer?
news
Exclusive speaker interview with Professor Nagy Habib – MiNA Therapeutics/Imperial College London
SMi are delighted to have, Nagy Habib, Head of HPB Surgery, Imperial College London and Co-Founder, MiNA Therapeutics, as the Keynote Address for day 1 at RNA Therapeutics 2018!
news
Charles River Laboratories presents newly expanded capabilities at Neuroscience 2017
Charles River Laboratories International, Inc. announced that its team of neuroscience drug discovery experts is presenting 27 scientific posters, both independently and collaboratively with clients, at Neuroscience 2017, the 47th annual meeting of the Society for Neuroscience (SfN).
